Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.76|
|52 Week High||US$2.30|
|52 Week Low||US$24.57|
|1 Month Change||12.45%|
|3 Month Change||6.57%|
|1 Year Change||228.09%|
|3 Year Change||415.29%|
|5 Year Change||606.45%|
|Change since IPO||32.23%|
Recent News & Updates
|VERU||US Personal Products||US Market|
Return vs Industry: VERU exceeded the US Personal Products industry which returned 47.1% over the past year.
Return vs Market: VERU exceeded the US Market which returned 31.5% over the past year.
Stable Share Price: VERU is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VERU's weekly volatility has decreased from 17% to 9% over the past year.
About the Company
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer.
Veru Fundamentals Summary
|VERU fundamental statistics|
Is VERU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VERU income statement (TTM)|
|Cost of Revenue||US$12.18m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0019|
|Net Profit Margin||-0.25%|
How did VERU perform over the long term?See historical performance and comparison
Is Veru undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: VERU ($8.76) is trading above our estimate of fair value ($0.53)
Significantly Below Fair Value: VERU is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: VERU is unprofitable, so we can't compare its PE Ratio to the US Personal Products industry average.
PE vs Market: VERU is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VERU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VERU is overvalued based on its PB Ratio (4.5x) compared to the US Personal Products industry average (2.7x).
How is Veru forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VERU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VERU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VERU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VERU's revenue (40.7% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: VERU's revenue (40.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VERU's Return on Equity is forecast to be high in 3 years time
How has Veru performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VERU is currently unprofitable.
Growing Profit Margin: VERU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VERU is unprofitable, and losses have increased over the past 5 years at a rate of 6.6% per year.
Accelerating Growth: Unable to compare VERU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VERU is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (54.7%).
Return on Equity
High ROE: VERU has a negative Return on Equity (-0.092%), as it is currently unprofitable.
How is Veru's financial position?
Financial Position Analysis
Short Term Liabilities: VERU's short term assets ($154.4M) exceed its short term liabilities ($17.2M).
Long Term Liabilities: VERU's short term assets ($154.4M) exceed its long term liabilities ($7.9M).
Debt to Equity History and Analysis
Debt Level: VERU's debt to equity ratio (7.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if VERU's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VERU has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if VERU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Veru current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VERU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VERU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VERU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VERU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: VERU is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VERU's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mitch Steiner (60 yo)
Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...
CEO Compensation Analysis
Compensation vs Market: Mitch's total compensation ($USD1.26M) is below average for companies of similar size in the US market ($USD2.39M).
Compensation vs Earnings: Mitch's compensation has increased whilst the company is unprofitable.
Experienced Management: VERU's management team is considered experienced (3.4 years average tenure).
Experienced Board: VERU's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VERU insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.3%.
Veru Inc.'s employee growth, exchange listings and data sources
- Name: Veru Inc.
- Ticker: VERU
- Exchange: NasdaqCM
- Founded: 1971
- Industry: Personal Products
- Sector: Household
- Market Cap: US$699.519m
- Shares outstanding: 79.85m
- Website: https://www.verupharma.com
Number of Employees
- Veru Inc.
- 48 NW 25th Street
- Suite 102
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 22:33|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.